自体造血干细胞移植治疗恶性淋巴瘤的初步临床观察  

Clinical observation of autologous hematopoietic stem cell transplantation for malignant lymphoma

作　　者：倪淑琴[1] 田禾[1] 牛作兴[1] 毕文[1] 刘新元[1] 王云[1] 张健[1] 

机构地区：[1]山东省肿瘤医院造血干细胞移植中心,山东济南250117

出　　处：《中华肿瘤防治杂志》2009年第17期1332-1334,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨自体造血干细胞移植(AHSCT)治疗恶性淋巴瘤的疗效。方法:造血干细胞动员采集方案采用移植前化疗敏感方案,如CHOP、DICE和ESHAP,大剂量阿糖胞苷(HD-Ara-C)等联合粒细胞集落刺激因子(G-CSF),预处理则采用BEAC(BCNU、VP-16、Ara-C和CTX)方案。结果:所有患者均采集到足够造血干细胞数,CD34+平均为2.7×108kg-1。移植后所有患者均恢复造血并出现Ⅳ度骨髓抑制,移植相关死亡率为0。移植后8例CR,3例PR。先后有2例进展(复发),其中1例死亡。中位随访时间为24.6个月,2年总生存率为84.6%。结论:AHSCT是一种有效治疗恶性淋巴瘤的方法,安全性好,但对于高危患者仍需探讨新的方法。OBJECTIVE：To evaluate the therapeutic effect of autologous hematopoietic stem cell transplantation （AHSCT） on malignant lymphoma. METHODS： Hematopoietic stern cells were mobilized and eol leered by granulocyte colony stimulating factor（G-CSF） combined with chemotherapy which included chemo sensitive drugs such as CHOP, DICE, ESHAP, HD-Ara C, crag. The conditioning regimen was BEAC （carmustine, etoposide, cyclophosphamide, cytarabine）. RESULTS： Enough hematopoietic stem cells were collected from all the patients, and average CD34^＋ was 2. 7 × 10^8 kg ^-1. Thfrteen patients had reconstituted bone marrow hematopoiesis after transplantation and appeared IV mylodepressing, and there was no transplantation-related mortality. Eight and three patients achieved complete remission （CR） and partial remission respectively （PR）. Two patients relapsed or progressed and one died of the disease. The median follow-up time was 24.6 months, and overall 2-year surviva rate was 84.6%. CONCLUSIONS： AHSCT is an effective approach in the treatment of some patients with chemo sensitive malignant lymphoma and has a good salty. However, further studies are still needed to investigate new therapies for patients with poor prognosis.

关 键 词：抗肿瘤药/投药和剂量 淋巴瘤/药物疗法 输血 自体 造血干细胞 综合疗法 

分 类 号：R733.1[医药卫生—肿瘤]